Background: Recent studies have shown substantial increases in the survival of AIDS patients in developed countries and in Brazil as a result of antiretroviral therapy (ART) and prophylaxis for opportunistic infections. This study compares survival rates using the Brazilian Ministry of Health 2004 and Centers for Disease Control and Prevention (CDC) 1993 case definitions in a large HIV/AIDS referral centre in Rio de Janeiro.
Introduction
Recent studies have shown that the survival of patients with AIDS in Brazil has been increasing substantially, as observed in developed countries, mainly as a result of the universal access to antiretroviral therapy (ART) [1] [2] [3] [4] .
Several criteria have been used to define AIDS. Brazil initially used the case definition established by the Centers for Disease Control and Prevention (CDC) USA, but later adopted its own case definition, which combines an assessment of clinical conditions, the presence or absence of defining diseases and immunological status [5] . In accordance with Brazil Most study patients have adopted the CDC case definition [6] , but considering Brazil's unique position as a developing country with more than 135 000 patients under ART [7] , it becomes relevant to analyse the survival of these patients using both a case definition that enables comparisons with international studies and one adapted to Brazil's specific conditions. The present study makes such a comparison in a referral unit within a large biomedical research centre, the Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro.
Methods
A cohort of AIDS patients was followed at the Evandro Chagas Clinical Research Institute (IPEC-FIOCRUZ) between 1986 and 2002. Cases, defined by either the CDC or Ministry of Health definitions, which progressed to AIDS by 31 December 2003, were considered for the present analysis. Individuals less than 13 years of age or with less than 15 days of follow-up were excluded from the analysis.
The outcome studied was death from an AIDS-related cause. Survival was calculated as the time elapsed from the date of AIDS diagnosis until the data of death or the last attendance. Deaths from causes unrelated to AIDS, cases with loss of follow-up, and individuals who stayed alive until the end of the study period were censored at the last date documented to be alive.
The following covariates were considered: sex; education level; age at AIDS diagnosis; exposure category [8] ; initial stage of disease; prophylaxis for opportunistic infections; initial and last ART; and the period when the diagnosis was made. The clinical stage of disease at the first visit was classified as AIDS and non-AIDS. For individuals who presented with more than one defining condition, a hierarchy was established such that the immunological status had primacy over the defining disease, and disease over the Ministry of Health scoring.
ART use was categorized as: monotherapy; combined therapy, when two or more nucleoside reverse transcriptase inhibitors were used; and highly active antiretroviral therapy (HAART), when at least one non-nucleoside reverse transcriptase inhibitor or protease inhibitor was used. The category 'without therapy' comprised those who died or were lost to follow-up before 1990, had no indication for therapy, or refused treatment. The period of diagnosis was categorized in relation to when antiretroviral drugs and HAART therapy were first available: up to 1990 (before ART), 1991-1995 (mono/ double therapy), and from 1996 onwards (HAART). The survival functions were described and compared using the probabilities of survival for 1 and 5 years after AIDS diagnosis, using the Kaplan-Meier method and the log rank test [9] . The Wald test was used to define the variables to be entered into the Cox model. The stepwise method was used to fit the model, assessing the maximum likelihood in each step [10] .
Results
Subjects included 1415 cases diagnosed up to 31 December 2003. Of these, 445 patients (31%) died, 205 (14%) were lost of follow-up, and 765 (55%) were alive as of the end of the study. Of the cases that progressed to death, 393 (88%) were AIDS-related and 52 (12%) were from unrelated or unknown causes. The mean age at the baseline was 35 years. There were 468 female cases in the study (33%). The majority of the patients had less than 8 years of education.
The Ministry of Health case definition identified 289 cases that did not meet the CDC criteria. The opposite happened in only 16 cases.
Three-quarters of patients (75%) were still alive 22 months [95% confidence interval (CI) 19-26] after AIDS diagnosis according to the CDC case definition and 31 months (95% CI 26-36) according to the Ministry of Health case definition. Because the vast majority of AIDS patients were still alive at the study end, it was not possible to estimate the median length of survival using either case definition (Fig. 1) .
In bivariate analysis, using either case definition: female sex; absence of baseline clinical syndrome; AIDS case definition via immunological status; prophylaxis for tuberculosis, pneumocystosis and toxoplasmosis; any use of HAART; and diagnosis after 1995 were predictors of longer survival.
In multivariate analysis, the absence of a baseline clinical syndrome and any use of HAART were predictors of longer survival for both case definitions. For the Ministry of Health criteria, the initial stage of the case was also identified as a predictor of longer survival (Table 1) .
Discussion
The study highlights a substantial increase in survival after the introduction of HAART. Among international studies, the greatest survival encountered in recent years comes from the study by Dore et al. [11] , in Australia, with cases defined between 1993 and 2000, using the CDC case definition. For patients diagnosed in 1993/ 1995, the median survival was estimated as 20 months and 40 months for the period 1996/2000. Our findings compare favourably.
Recent studies [2, 3] have already given evidence of a substantial increase in the estimated survival of individuals living with AIDS in Brazil. However, comparing the two definitions, longer survival was shown by the Ministry of Health than by the CDC criteria. These findings may be explained, partly, by using a CD4 cell cut-off of 350 cells/ml in the Ministry of Health case definition rather than 200 cells/ml, as in the CDC case definition.
The absence of a baseline clinical syndrome and any use of HAART were shown to be associated with a greater probability of survival for both case definitions, but the initial stage of the case was found to be associated with survival only when the Ministry of Health case definition was considered.
We believe that the longer survival found in the present study, in relation to previous Brazilian studies, is mainly caused by the continuous improvement in the types and delivery of treatment. We also believe that the longer survival is partly the result of the excellence of care at the study institution. On the other hand, the findings do not seem to be associated with the initiation of antiretroviral drugs at earlier stages of immunodepression. Recent studies suggest that initiating ART at this level does not impact survival [12] as much as the effective use of antiretroviral drugs. Unfortunately, the study did not appraise antiretroviral adherence.
In the present study, the longer survival initially found for women did not remain significant in the multivariate analysis. The apparent improved survival may have been confounded by the increase in the numbers of cases among women in recent years, when the use of combined therapy or HAART and prophylaxis for opportunistic infections came into common use. Similar results were found in a study conducted in the USA in 2001 [4] .
For both criteria utilized, the defining condition for AIDS determined significant differences in survival, with longer survival for cases defined by immunological status. Corroborating other studies [4, 12, 13] , the present results suggest that early follow-up, with cases defined by immunological status rather than disease allows for the timely identification of indications to initiate therapies and prophylaxis and therefore longer survival.
Survival was significantly greater for patients who had had prophylaxis for Pneumocystis jirovecii pneumonia, tuberculosis and toxoplasmosis for both case definitions. Similar results have been found in other studies conducted in Brazil that evaluated prophylaxis for Pneumocystis jiroveciii pneumonia [3, [14] [15] [16] .
We observed a temporal increase in survival over time in bivariate analysis. Compared with the period after 1996, the risk of death was more than ninefold for cases diagnosed up to 1990, and fourfold for the period 1991-1999, for both case definitions. These results agree with those of other authors [3, 4, 11, [17] [18] [19] . The period of diagnosis was not included in the final multivariate model because of its collinearity with the treatment using antiretroviral drugs. Our study did not examine survival from HIV diagnosis on. Survival expectations from this point should be longer because the use of treatment before diagnosis is likely to lengthen the time to AIDS. However, AIDS achieved after the initiation of treatment may be associated with severe immunosuppression and treatment failure and therefore shortened survival time after AIDS. Our study population may not be typical of other areas of Brazil. To the extent that a higher quality of care may be delivered to this population, survival may better than elsewhere.
The present findings reinforce the importance of stimulating qualified medical assistance at an early stage, with the utilization of antiretroviral and prophylactic therapy and close monitoring. It is also important to emphasize that the choice of criteria for case definition directly impacts on the results obtained. The simultaneous use of the CDC and Ministry of Health case definitions provided evidence of distinct survival lengths and allowed comparisons with international studies.
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